Effects of EPHX1 and CYP3A4*22 genetic polymorphisms on carbamazepine metabolism and drug response among Tunisian epileptic patients

References

• Arroyo, A.S., Brodie, M.J., Avanzini, G., Baumgartner, C., Chiron, C., Dulac, O., … , Serratosa, J.M. (2002). Is refractory epilepsy preventable? Epilepsia, 43, 437–444.
   PubMed Web of Science ®Google Scholar
• Bu, H.Z., Kang, P., Deese, A.J., Zhao, P., & Pool, W.F. (2005). Human in vitro glutathionyl and protein adducts of carbamazepine-10,11-epoxide, a stable and pharmacologically active metabolite of carbamazepine. Drug Development and Iindustrial Pharmacy, 33, 1920–1924.
   Google Scholar
• Caruso, A., Bellia, C., Pivetti, A., Agnello, L., Bazza, F., Scazzone, C., …, Ciaccio, M. (2014). Effects of EPHX1 and CYP3A4 polymorphisms on carbamazepine metabolism in epileptic patients. Pharmacogenomics and Personalized Medicine, 7, 117–120.
   PubMedGoogle Scholar
• Chbili, C., Bannour, S., Khlifi, S., Ben Hadj Ali, B., & Saguem, S. (2014). Relationships between pharmacokinetic parameters of carbamazepine and therapeutic response in patients with bipolar disease. Annales de Biologie Clinique (Paris), 72, 453–459.
   PubMed Web of Science ®Google Scholar
• Chbili, C., Hassine, A., Ben Amor, S., Nouira, M., Ben Ammou, S., & Saguem, S. (2015). Relationships between pharmacokinetic parameters of carbamazepine and therapeutic response in epileptic patients. Archives of Medical Sciences
   Google Scholar
• Daci, A., Beretta, G., Vllasaliu, D., Shala, A., Govori, V., Norata, G.D., & Krasniqi, S. (2015). Polymorphic variants of SCN1A and EPHX1 influence plasma carbamazepine concentration, metabolism and pharmacoresistance in a population of Kosovar Albanian epileptic patients. PLoS One, 10, e0142408.
   Web of Science ®Google Scholar
• Elens, L., van Gelder, T., Hesselink, D.A., Haufroid, V., & van Schaik, R.H. (2013). CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy. Pharmacogenomics, 14, 47–62.
   PubMed Web of Science ®Google Scholar
• Hassett, C., Aicher, L., Sidhu, J.S., & Omiecinski, C.J. (1994). Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants. Human Molecular Genetics, 3, 421–428.
   PubMed Web of Science ®Google Scholar
• Hassett, C., Lin, J., Carty, C.L., Laurenzana, E.M., & Omiecinski, C.J. (1997). Human hepatic microsomal epoxide hydrolase: comparative analysis of polymorphic expression. Archives of Biochemistry and Biophysics, 337, 275–283.
   PubMed Web of Science ®Google Scholar
• He, X.J., Jian, L.Y., He, X.L., Tang, M., Wu, Y., Xu, Y.Y., … Zhao, L.M. (2014). Association of ABCB1, CYP3A4, EPHX1, FAS, SCN1A, MICA, and BAG6 polymorphisms with the risk of carbamazepine-induced Stevens–Johnson syndrome/toxic epidermal necrolysis in Chinese Han patients with epilepsy. Epilepsia, 55, 1301–1306.
   PubMed Web of Science ®Google Scholar
• Hung, C.C., Chang, W.L., Ho, J.L., Tai, J.J., Hsieh, T.J., Huang, H.C., … Liou, H.H. (2012). Association of polymorphisms in EPHX1, UGT2B7, ABCB1, ABCC2, SCN1A and SCN2A genes with carbamazepine therapy optimization. Pharmacogenomics, 13, 159–169.
   PubMed Web of Science ®Google Scholar
• Jaramillo, N.M., Galindo, I.F., Vázquez, A.O., Cook, H.J., LLerena, A., & López, M.L. (2014). Pharmacogenetic potential biomarkers for carbamazepine adverse drug reactions and clinical response. Drug Metabolism and Drug Interactions, 29, 67–79.
   PubMedGoogle Scholar
• Kitteringham, N.R., Davis, C., Howard, N., Pirmohamed, M., & Park, B.K. (1996). Interindividual and interspecies variation in hepatic microsomal epoxide hydrolase activity: studies with cis-stilbene oxide, carbamazepine 10,11-epoxide and naphthalene. The Journal of Pharmacology and Experimental Therapeutics, 278, 1018–1027.
   PubMed Web of Science ®Google Scholar
• Maekawa, K., Harakawa, N., Yoshimura, T., Kim, S.R., Fujimura, Y., Aohara, F., …, Saito, Y. (2010), CYP3A4*16 and CYP3A4*18 alleles found in East Asians exhibit differential catalytic activities for seven CYP3A4 substrate drugs. Drug Metabolism and Disposition: the Biological Fate of Chemicals, 38, 2100–2104.
   PubMed Web of Science ®Google Scholar
• Makmor-Bakry, M., Sills, G.J., Hitiris, N., Butler, E., Wilson, E.A., & Brodie, M.J. (2009). Genetic variants in microsomial epoxide hydrolase influence carbamazepine dosing. Clinical Neuropharmacology, 32, 205–211.
   PubMed Web of Science ®Google Scholar
• Monaco, F., & Cicolin, A. (1999), Interactions between anticonvulsant and psychoactive drugs. Epilepsia, 40, S71–S76.
   PubMed Web of Science ®Google Scholar
• Nakajima, Y., Saito, Y., Shiseki, K., Fukushima-Uesaka, H., Hasegawa, R., Ozawa, S., …, Sawada, J. (2005). Haplotype structures of EPHX1 and their effects on the metabolism of carbamazepine-10,11-epoxide in Japanese epileptic patients. European Journal of Clinical Pharmacology, 61, 25–34.
   PubMed Web of Science ®Google Scholar
• Ruzilawati, A.B., Suhaimi, A.W., & Gan, S.H. (2007). Genetic polymorphisms of CYP3A4: CYP3A4*18 allele is found in five healthy Malaysian subjects. International Journal of Clinical Chemistry, 383, 158–162.
   Google Scholar
• Saruwatari, J., Ishitsu, T., & Nakagawa, K. (2010). Update on the genetic polymorphisms of drug-metabolizing enzymes in antiepileptic drug therapy. Pharmaceuticals, 3, 2709–2732.
   Google Scholar
• Shovoron, S.D. (2000). Hanbook of the treatment of epilepsy. Oxford: UK Blackwell Science.
   Google Scholar
• Thorn, C.F., Leckband, S.G., Kelsoe, J., Leeder, J.S., Müller, D.J., Klein, T.E., & Altman, R.B. (2011). PharmGKB summary: carbamazepine pathway. Pharmacogenetics and Genomics, 21, 906–910.
   PubMed Web of Science ®Google Scholar
• Yun, W., Zhang, F., Hu, C., Luo, X., Xue, P., Wang, J., … Guo, Y. (2013). Effects of EPHX1, SCN1A and CYP3A4 genetic polymorphisms on plasma carbamazepine concentrations and pharmacoresistance in Chinese patients with epilepsy. Epilepsy Research, 107, 231–237.
   PubMed Web of Science ®Google Scholar
• Zaied, C., Abid, S., Mtiraoui, N., Zellema, D., Achour, A., & Bacha, H. (2012). Cytochrome P450 (CYP3A4*18) and glutathione-S-transferase (GSTP1) polymorphisms in a healthy Tunisian population. Genetic Testing and Molecular Biomarkers, 16, 1184–1187.
   PubMed Web of Science ®Google Scholar
• Zhu, X., Yun, W., Sun, X., Qiu, F., Zhao, L., & Guo, Y. (2014). Effects of major transporter and metabolizing enzyme gene polymorphisms on carbamazepine metabolism in Chinese patients with epilepsy. Pharmacogenomics, 15, 1867–1879.
   PubMed Web of Science ®Google Scholar